[Skip to Content]
[Skip to Content Landing]
November 2015

Opportunities for New Drug Development in PsychiatryA Glass Half-Full

Author Affiliations
  • 1Neuroscience and Pain Research Unit, BioTherapeutics Research and Development, Pfizer Inc, Cambridge, Massachusetts
JAMA Psychiatry. 2015;72(11):1067-1068. doi:10.1001/jamapsychiatry.2015.1735

Despite having revolutionized patient care in the past 50 years, drug discovery and development in psychiatry has been in crisis. Key challenges are well known and include target identification and validation, appropriate use of animal models, development of biomarkers for patient stratification and end point selection, overcoming regulatory hurdles, ensuring reliability and reproducibility of data, and fostering data sharing and collaboration.1 Addressing these challenges remains a difficult undertaking, but emerging approaches for drug discovery and development in neuroscience by pharmaceutical and biotech companies offer reason for optimism. We provide below a short perspective of steps to accelerate innovation and advance new medicines for psychiatric disease.

First Page Preview View Large
First page PDF preview
First page PDF preview